FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 307:1481-1486 December 9, 1982 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We evaluated the efficacy of hepatitis B vaccine (Heptavax-B) containing only the ad subtype in a randomized, placebo-controlled, double-blind trial among 865 staff members of 43 hemodialysis units in the United States. Surface antibody developed in 92.6 per cent of the subjects after two doses of vaccine and in 96 per cent after the six-month booster. The incidence of infections with hepatitis B virus (with or without hepatitis) was 9.9 per cent in placebo recipients and 2.2 per cent in vaccine recipients (P less than 0.01). The two cases of hepatitis B among vaccine recipients did not occur in subjects in whom antibody had developed. In 81 per cent of the hepatitis events, the virus was of the ay subtype. The indicence of ay virus was 8.2 per cent among placebo recipients and 1.2 per cent among vaccine recipients (P less than 0.005). We conclude that these data confirm the efficacy of the vaccine and demonstrate subtype cross-protection.

This article has been cited by other articles:

• Kim, H N., Harrington, R. D, Rompaey, S. E V., Kitahata, M. M (2008). Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 19: 600-604 [Abstract] [Full Text]  
• Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y. (2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA 10.1073/pnas.191617598v1 [Abstract] [Full Text]  
• Walsh, K, Alexander, G J M (2001). Update on chronic viral hepatitis. Postgrad. Med. J. 77: 498-505 [Abstract] [Full Text]  
• Verrier, F., Burda, S., Belshe, R., Duliege, A.-M., Excler, J.-L., Klein, M., Zolla-Pazner, S. (2000). A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates. J. Virol. 74: 10025-10033 [Abstract] [Full Text]  
• Hicks, R. A., Cullen, J. W., Jackson, M. A., Burry, V. F. (1989). Hepatitis B Virus Vaccine: Cost-Benefit Analysis of its Use in a Children's Hospital. CLIN PEDIATR 28: 359-365 [Abstract]  
• Kuo, G, Choo, Q., Alter, H., Gitnick, G., Redeker, A., Purcell, R., Miyamura, T, Dienstag, J., Alter, M., Stevens, C., et, al. (1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362-364 [Abstract]  
• Reese, C. E., Ockner, R. K. (1989). Prevention of Hepatitis B in Surgeons and Their Patients. PERSPECT VASC SURG ENDOVASC THER 2: 138-147  
• Neurath, A., Kent, S., Strick, N (1984). Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science 224: 392-395 [Abstract]  
• Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y. (2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA 98: 11539-11544 [Abstract] [Full Text]